Turn Therapeutics Inc. · NASDAQ:TTRX
Turn Therapeutics — Investor Presentation (November 2026)
37 slides from Turn Therapeutics's investor presentation, Nov 10, 2026
Slide 1: November 2026 Corporate Presentation
November 2026 Corporate Presentation
Slide 2: Forward-Looking Statements & Safe Harbor
Forward - Looking Statements & Safe Harbor Except for historical information set forth herein, the matters set forth in this presentation contain forward - looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward - look
Slide 3: PermaFusion: API-Agnostic Delivery Platform
Patented Multi - Step Mixing Process w/out Emulsifier Petro / Oil Carrier API in Liquid Solvent 3 PermaFusion: API - Agnostic Delivery Platform A potentially transformative delivery platform enabling stable, emulsifier - free dispersion of active ingredients in oil - based carriers for superior pene
Slide 4: Executive Summary
Executive Summary Turn Therapeutics is a biotechnology company developing GX - 03, a potential first - in - class, precision, non - systemic immunomodulation therapy that targets IL - 36 and key downstream cytokines to address high - unmet - need inflammatory diseases, with an initial focus on moder
Slide 5: Turn Tx Pipeline
Turn Tx Pipeline Expected ph 2 topline results (Q1 2027) PRECLINICAL PHASE I PHASE 2 PHASE 3 Upcoming Milestones 1 Moderate - to - Severe Atopic Dermatitis (AD) Q1 2027: Topline Readout Mid - 2027: Phase 3 initiation GX - 03 IL - 36 α , IL - 36 γ , IL - 31 and IL - 4 inhibitor Non - systemic and non
Slide 6: Atopic Dermatitis Program
GX - 03 for AD Phase 2 Ongoing IL - 4 IL - 31 IL - 36 6
Slide 7: The Chronic Inflammatory Loop
7 The Chronic Inflammatory ‘Loop’ Skin Barrier Disruption Skin barrier disruption results in release of IL - 36 IL - 36 IL - 31 Drives Itch & Scratch IL - 31 release drives TH2 IL - 31 itch which leads to IL - 4, further disruption IL - 13, of the skin barrier IL - 31 and restarts loop Chronic AD Cy
Slide 8: Stop the Loop
Stop the ‘Loop’ GX - 03 Inhibition IL - 36 and IL - 31 Inhibition GX - 03 targets key upstream and downstream cytokines to stop the chronic inflammatory ‘loop’ GX - 03 suppresses IL - 36 release via targeted modulation of the epithelial microenvironment, blunting Th2 response GX - 03 suppresses IL -
Slide 9: Ongoing Adaptive Phase 2a/2b in AD
Ongoing Adaptive Phase 2a/2b for GX - 03 in AD Phase 2a N ≈ 50 - 1:1 Randomized - Double - blind - Wide Inclusion - Age: 18 - 80 - BID Topical - IDMC Governed Phase 2a/Stage 1 Results Broad Inclusion Criteria (vIGA≥3 OR EASI≥7.0) n = 50 (ITT) | GX - 03 = n 27 | Vehicle = n 23 Phase 2b N ≈ 120 - 136
Slide 10: How is Atopic Dermatitis Severity Measured?
How is Atopic Dermatitis Severity Measured? Lesion Severity vs Inflammatory Burden Lesion Severity Measured through vIGA - AD Inflammatory Burden Measured through EASI ▪ Validated Investigator Global Assessment (vIGA - AD) : A 5 point scale (0 - 4) rating overall disease severity based on the worst
Slide 11: Enrichment for PP-NRS≥7 Produced Stronger Treatment Separation
Enrichment for PP - NRS≥7 Produced Stronger Treatment Separation in Key Efficacy Endpoints Week 8 EASI - 100 (Complete Clearance) Week 8 EASI - 90 (≥90% Improvement from Baseline) Week 4 EASI - 75 (≥75% Improvement from Baseline) Week 4 vIGA - AD Success (vIGA of 0/1 with ≥ 2 grade improvement) Δ 23
Slide 12: Stage 2/Phase 2b Design
Stage 2/Phase 2b Design Optimized Design Baseline EASI 1.1 - 7 N= ~60 1:1 Randomized Baseline EASI 7.1 - 15.9 N= ~60 1:1 Randomized Three Targeted Enrollment Groups Stratified by Baseline EASI Baseline EASI ≥ 16 N= ~16 1:1 Randomized Enrollment continued during Stage 1 Analysis and Stage 2 Optimizat
Slide 13: Stage 2/Phase 2b – Representative Subgroup from Phase 2a
Stage 2/Phase 2b – Representative Subgroup from Phase 2a Baseline EASI ≥ 1.1 and Baseline PP - NRS ≥ 7 Legends: GX - 03 Vehicle SD – GX - 03 SD – Vehicle Vehicle (n=12) GX - 03 (n=13) Baseline Characteristics 7.2 (5.7) 12.1 (13.3) Mean EASI (SD) 3.08 (0.49) 3.15 (0.36) Mean vIGA (SD) Baseline charac
Slide 14: Stage 2/Phase 2b – Representative Subgroup from Phase 2a
Stage 2/Phase 2b – Representative Subgroup from Phase 2a Baseline EASI ≥ 1.1 and Baseline PP - NRS ≥ 7 *Fisher’s Exact Test Stage 2 Statistical Power at n ≈ 135 Two - Sided p - value* Treatment Difference Vehicle (n=12) GX - 03 (n=13) Stage 2 Selected Endpoints ~99.99% 0.0123 Δ 53.2% 8.3% (1/12) 61.
Slide 15: Phase 2a – Safety Summary
Phase 2a – Safety Summary GX - 03 N = 27 Vehicle N = 23 Subjects with AE, n Severe (Grade ≥ 2) Serious AEs AEs leading to study drug discontinuation 1* 0 0 0 1** 0 0 0 * Subject reported a mild warming sensation that was described as pleasant. ** Subject reported a common cold which was determined b
Slide 16: AD TAM & Prevalence
AD TAM & Prevalence 16.5M US patients suffer from AD 1 6.6M patients in moderate - severe category 1 AD is the largest and fastest growing I&I market in the U.S. 2 1. The National Eczema Association (NEA) 2. Largest by patient population, fastest based on projected market size (EvaluatePharma) 3. ht
Slide 17: For Patients Across The Full Moderate-Severe AD Spectrum
GX - 03: For Patients Across The Full Moderate - Severe AD Spectrum Lower EASI (1.1 – 7) Patients with clinically moderate - severe lesions per vIGA are not all eligible for the same treatments based upon current guidelines Higher EASI (>20) Moderate, Limited IGA 3/4 - EASI 1.1 - 3 Moderate, Scatter
Slide 18: Onychomycosis Program: Phase 3 Ready
GX - 03 for Onychomycosis Phase 3 Ready 18
Slide 19: Human Data in Onychomycosis
19 GX - 03 – Human Data in Onychomycosis Before After “Novel Approach to Polymicrobial Nail Infection” R. Dan Davis, DPM Former President of American Podiatric Medical Association Study Design (n ≈ 100) • GX - 03 applied once daily or BID application • No debridement or occlusive dressings required
Slide 20: Current Topicals for Onychomycosis
Current Topicals for Onychomycosis 1. https://pubmed.ncbi.nlm.nih.gov/21555762/ 2. Complete cure is defined as 0% involvement of the target toenail (no clinical evidence of onychomycosis of the target toenail). 3. Not studied in head - to - head trials with GX - 03 20 In the same in - vivo model, GX
Slide 21: Onychomycosis TAM & Prevalence
Onychomycosis TAM & Prevalence Less than 30% of the affected population seeks treatment due to lack of awareness, limited efficacy and hepatotoxicity of available therapeutics 4 US Market Size 2 21 High Unmet Needs • Effective therapies as current topical treatments are only 6 - 18% effective • Pate
Slide 22: Planned Phase 3 Pivotal Trial
Planned Phase 3 Pivotal Trial Q4 2028 Topline Results Expected Q2 2027 First Patient Dosing Planned 1H 2028 Interim Analysis Expected o Mycological Cure at Week 52 o < 5% Clinical Involvement at Week 52 o < 5% Mycological Involvement at Week 52 Population: • N ≈ 250 • Age: 18 – 80 • No concomitant t
Slide 23: Hidradenitis Suppurativa (HS) Preclinical Stage
GX - 03 for Hidradenitis Suppurativa (HS) Preclinical Stage IL - 36 23
Slide 24: HS – Major I&I Challenge with Significant Unmet Need
HS – Major I&I Challenge with Significant Unmet Need Early Nodule Abscess Draining Tunnels HS Progression Inflammatory Burden HS is an IL - 36 driven chronic, inflammatory, recurrent skin disease that causes follicular occlusion and rupture leading to painful inflammatory nodules and abscesses GX -
Slide 25: Planned Phase 2a Trial in HS
GX - 03 – Planned Phase 2a Trial in HS 25 Trial Design 1 Q1 2027 First Patient Dosing Planned post - baseline visits Population • 40 GX - 03:40 Vehicle (1:1, stratified by baseline disease severity) • Adults with Hurley Stage I/II • Topical GX - 03 applied BID (vs matched vehicle) for 16 weeks Study
Slide 26: HS – TAM & Prevalence
HS – TAM & Prevalence 26 High Unmet Need ~900K adults diagnosed with HS 1 Market Size 3 $7.8B 15.6% CAGR 3x more common in women than men 1 ▪ Safe, non - systemic therapies ▪ Lower cost treatment options ▪ Limited approved treatment options for children ▪ Tachyphylaxis and treatment durability 70% o
Slide 27: Future Clinical Milestones
GX - 03 – Future Clinical Milestones 1 2026 2027E 2028E Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 AD Atopic Dermatitis HS Hidradenitis Suppurativa Onychomycosis Toe - nail Fungus Ph 2 Topline Results Ph 3 Initiation Ph 2a Initiation Ph 2a Topline Results Ph 3 Initiation Interim Results Ph 3 Topline Results Cash Ru
Slide 28: Financial & IP Highlights
Financial & IP Highlights $10.4M Cash Balance As of September 30, 2026 Cash Runway into Q3 2027 Additional capital available under existing facilities ~30.5M Common Shares Outstanding As of September 30, 2026 ~$1M/qtr Current G&A burn as a public co. Extensive Patent Families Various patent families
Slide 29: Management & Board
Management & Board Key Management Bradley Burnam CEO, Chairman & Founder Dr. Neil Ghodadra, MD Chief Medical Officer Dr. Robert Redfield, MD Chief Scientific Officer Dr. Stephen Hahn, MD Clinical and Regulatory Lead Sasha Damouni Ellis Corporate Communications & IR Zuraiz Chaudhary Chief Accounting
Slide 30: Thank You!
[email protected] 250 N. Westlake Blvd, #210 Westlake Village, CA 91362 Thank You!
Slide 31: Appendix: In-vivo and Safety Study
Appendix In - vivo and Safety Study 31
Slide 32: 57% Reduction in Disease Severity in an IL-36 Environment
57% Reduction in Disease Severity in an IL - 36 Environment 1 N = 30 Inflammation induced using a standardized epicutaneous Staphylococcus aureus exposure protocol Group 1 N = 10 Pre - treatment Control Group 2 N = 10 No Treatment Control Group 3 N = 10 GX - 03 Treatment 3.33 ~ Mean IGA after 7 days
Slide 33: Observed Inhibition of Key Upstream and Downstream Cytokines
Observed Inhibition of Key Upstream and Downstream Cytokines IL - 36 α Protein Expression (Raw Integrated Density) Objective: To ascertain the immunological inhibitory effects of GX - 03 for upstream and downstream cytokines N = 36 Group 1: no treatment (N = 18) Group 2: GX - 03 treatment (N = 18) I
Slide 34: Phase-Level Safety Data: RIPT Study
Phase 1 - Level Safety Data: 53 Patients RIPT Study Trial Design • First application: 48 hours of continuous exposure • 2 nd through 9 th application: 24 hours of continuous exposure three times a week for three consecutive weeks Trial Results: No adverse reactions of any kind were reported during t
Slide 35: Appendix: Stage 1 Subgroup Analysis
Appendix Stage 1 Subgroup Analysis 35
Slide 36: Moderate-Severe AD: Assessing for Stage 2 EASI Enrichment
Moderate - Severe AD: Assessing for Stage 2 EASI Enrichment IGA 3/4 & Baseline EASI ≥ 10 Treatment Difference Vehicle (n=4) GX - 03 (n=9) Endpoint Δ 30.6% 25.0% (1/4) 55.6% (5/9) Week 4 vIGA - AD Success vIGA of 0/1 with ≥ 2 grade improvement Δ 38.9% 50.0% (2/4) 88.9% (8/9) Week 4 EASI - 75 Δ 27.8%
Slide 37: Interim Analysis – EASI 1.1 Subgroup
Interim Analysis – EASI 1.1 – 7 Subgroup Presents as Meaningful on Key Disease Clearance Endpoints Treatment Difference Vehicle (n=18) GX - 03 (n=14) Endpoints Δ 38.1% 33.3% (6/18) 71.4% (10/14) Week 4 vIGA - AD Success vIGA of 0/1 with ≥ 2 grade improvement Δ 23.1% 5.6% (1/18) 28.6% (4/14) Week 4 E
Turn Therapeutics — Investor Presentation (November 2026) on 6ix